{"id":"https://openalex.org/W1978670159","doi":"https://doi.org/10.1002/cncr.23056","title":"Medroxyprogesterone, interferon alfa\u20102a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial","display_name":"Medroxyprogesterone, interferon alfa\u20102a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial","alternate_titles":[],"publication_year":2007,"publication_date":"2007-10-11","ids":{"openalex":"https://openalex.org/W1978670159","doi":"https://doi.org/10.1002/cncr.23056","mag":"1978670159","pmid":"https://pubmed.ncbi.nlm.nih.gov/17932908"},"language":"en","primary_location":{"id":"doi:10.1002/cncr.23056","doi":"https://doi.org/10.1002/cncr.23056","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.23056","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23056","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1978670159"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23056","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020353650","display_name":"Sylvie N\u00e9grier","orcid":"https://orcid.org/0000-0002-0984-8505","observed_orcids":["https://orcid.org/0000-0002-0984-8505"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I203339264","display_name":"Universit\u00e9 de Lyon","ror":"https://ror.org/01rk35k63","country_code":"FR","type":"education","lineage":["https://openalex.org/I203339264"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Sylvie Negrier","raw_affiliation_strings":["Universit\u00e9 de Lyon, Department of Medical Oncology and Cytokines & Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France. negrier@lyon.fnclcc.fr","Universit\u00e9 de Lyon, Department of Medical Oncology and Cytokines & Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e9 de Lyon, Department of Medical Oncology and Cytokines & Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France. negrier@lyon.fnclcc.fr","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I203339264"]},{"raw_affiliation_string":"Universit\u00e9 de Lyon, Department of Medical Oncology and Cytokines & Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I203339264"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019588141","display_name":"David P\u00e9rol","orcid":"https://orcid.org/0000-0002-6429-7419","observed_orcids":["https://orcid.org/0000-0002-6429-7419"]},"institutions":[{"id":"https://openalex.org/I4210105738","display_name":"Centre L\u00e9on B\u00e9rard","ror":"https://ror.org/01cmnjq37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210105738"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"David Perol","raw_affiliation_strings":["Biostatistics Unit, Leon Berard Center, Lyon Cedex, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics Unit, Leon Berard Center, Lyon Cedex, France","institution_ids":["https://openalex.org/I4210105738"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040832651","display_name":"Alain Ravaud","orcid":"https://orcid.org/0000-0001-9455-6744","observed_orcids":["https://orcid.org/0000-0001-9455-6744"]},"institutions":[{"id":"https://openalex.org/I4210111110","display_name":"H\u00f4pital Saint-Andr\u00e9","ror":"https://ror.org/021959v84","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018323443","https://openalex.org/I4210111110"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Alain Ravaud","raw_affiliation_strings":["Saint Andre Hospital, University Hospital, Bordeaux Cedex, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saint Andre Hospital, University Hospital, Bordeaux Cedex, France","institution_ids":["https://openalex.org/I4210111110"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103187243","display_name":"Christine Chevreau","orcid":"https://orcid.org/0000-0002-4307-4179","observed_orcids":["https://orcid.org/0000-0002-4307-4179","https://orcid.org/0000-0001-9866-913X"]},"institutions":[{"id":"https://openalex.org/I4210128666","display_name":"Institut Claudius Regaud","ror":"https://ror.org/03pa87f90","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christine Chevreau","raw_affiliation_strings":["Claudius Regaud Center, Toulouse Cedex, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Claudius Regaud Center, Toulouse Cedex, France","institution_ids":["https://openalex.org/I4210128666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101896372","display_name":"Jacques\u2010Olivier Bay","orcid":"https://orcid.org/0000-0002-7032-5180","observed_orcids":["https://orcid.org/0000-0002-7032-5180"]},"institutions":[{"id":"https://openalex.org/I4210124119","display_name":"Centre Jean Perrin","ror":"https://ror.org/02pwnhd33","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124119"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jacques\u2010Olivier Bay","raw_affiliation_strings":["Jean Perrin Center, Clermont-Ferrand, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jean Perrin Center, Clermont-Ferrand, France","institution_ids":["https://openalex.org/I4210124119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112325300","display_name":"R. Delva","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Remy Delva","raw_affiliation_strings":["Paul Papin Center, Angers Cedex, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paul Papin Center, Angers Cedex, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069166380","display_name":"Emmanuel Sevin","orcid":"https://orcid.org/0009-0003-0702-7521","observed_orcids":["https://orcid.org/0009-0003-0702-7521"]},"institutions":[{"id":"https://openalex.org/I4210121964","display_name":"Centre Fran\u00e7ois Baclesse","ror":"https://ror.org/02x9y0j10","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210121964"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Emmanuel Sevin","raw_affiliation_strings":["Francois Baclesse Center, Caen Cedex, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Francois Baclesse Center, Caen Cedex, France","institution_ids":["https://openalex.org/I4210121964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002114271","display_name":"Armelle Caty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131356","display_name":"Centre Oscar Lambret","ror":"https://ror.org/03xfq7a50","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210131356","https://openalex.org/I4210141925"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Armelle Caty","raw_affiliation_strings":["Oscar Lambret Center, Lille Cedex, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oscar Lambret Center, Lille Cedex, France","institution_ids":["https://openalex.org/I4210131356"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049672639","display_name":"Bernard J. Escudier","orcid":"https://orcid.org/0000-0002-4626-0479","observed_orcids":["https://orcid.org/0000-0002-4626-0479"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Bernard Escudier","raw_affiliation_strings":["Gustave Roussy Institute, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Institute, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5020353650"],"corresponding_institution_ids":["https://openalex.org/I154526488","https://openalex.org/I203339264"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":null,"fwci":14.4662,"has_fulltext":true,"cited_by_count":199,"citation_normalized_percentile":{"value":0.9938096,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"110","issue":"11","first_page":"2448","last_page":"2457"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.9580000042915344},{"id":"https://openalex.org/keywords/medroxyprogesterone-acetate","display_name":"medroxyprogesterone acetate","score":0.9580000042915344},{"id":"https://openalex.org/keywords/interferon-alfa-2a","display_name":"interferon alfa-2a","score":0.9860000014305115},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.9959999918937683},{"id":"https://openalex.org/keywords/cytokine-therapy","display_name":"cytokine therapy","score":0.8069999814033508},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9649999737739563},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.7429999709129333},{"id":"https://openalex.org/keywords/angiogenesis-inhibitors","display_name":"angiogenesis inhibitors","score":0.8849999904632568}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9419314861297607},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6423404216766357},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6171555519104004},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5678678154945374},{"id":"https://openalex.org/C2781228144","wikidata":"https://www.wikidata.org/wiki/Q6046441","display_name":"Interferon alfa","level":4,"score":0.5255521535873413},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5032870173454285},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.47496291995048523},{"id":"https://openalex.org/C2776306185","wikidata":"https://www.wikidata.org/wiki/Q2823834","display_name":"Medroxyprogesterone acetate","level":3,"score":0.4337875247001648},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.4268611669540405},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3933563530445099},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.37871241569519043},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34673765301704407},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.34428757429122925},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3162376880645752},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2556511461734772},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.2341466248035431},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1658971905708313},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.08611154556274414},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008525","descriptor_name":"Medroxyprogesterone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/cncr.23056","doi":"https://doi.org/10.1002/cncr.23056","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.23056","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23056","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},{"id":"pmid:17932908","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17932908","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/cncr.23056","doi":"https://doi.org/10.1002/cncr.23056","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.23056","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23056","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1978670159.pdf","grobid_xml":"https://content.openalex.org/works/W1978670159.grobid-xml"},"referenced_works_count":39,"referenced_works":["https://openalex.org/W37165807","https://openalex.org/W1570622790","https://openalex.org/W1666874820","https://openalex.org/W1755178355","https://openalex.org/W1769511668","https://openalex.org/W1928193662","https://openalex.org/W1971211622","https://openalex.org/W1979300931","https://openalex.org/W1994351520","https://openalex.org/W1994486232","https://openalex.org/W2016185817","https://openalex.org/W2031738783","https://openalex.org/W2031820554","https://openalex.org/W2034932355","https://openalex.org/W2038252730","https://openalex.org/W2047301850","https://openalex.org/W2047318784","https://openalex.org/W2056606835","https://openalex.org/W2070727225","https://openalex.org/W2084812001","https://openalex.org/W2098136315","https://openalex.org/W2117838810","https://openalex.org/W2133157945","https://openalex.org/W2153896287","https://openalex.org/W2165254830","https://openalex.org/W2167571044","https://openalex.org/W2167805334","https://openalex.org/W2171469612","https://openalex.org/W2322553446","https://openalex.org/W2334694951","https://openalex.org/W2399474082","https://openalex.org/W2768600953","https://openalex.org/W2995133996","https://openalex.org/W3147894994","https://openalex.org/W4242783685","https://openalex.org/W4285719527","https://openalex.org/W4298379398","https://openalex.org/W4302458276","https://openalex.org/W6712476433"],"related_works":["https://openalex.org/W2132625873","https://openalex.org/W2334694951","https://openalex.org/W2589956807","https://openalex.org/W2294866259","https://openalex.org/W1875468008","https://openalex.org/W2040653258","https://openalex.org/W2268057227","https://openalex.org/W2171469612","https://openalex.org/W42863820"],"abstract_inverted_index":{"BACKGROUND:":[0],"Few":[1],"randomized":[2,59],"trials":[3],"have":[4],"compared":[5],"the":[6,49,170,186],"survival":[7,41,167,226],"benefit":[8,42,227],"of":[9,51,88,110,129,232,241],"interferon-alfa":[10,71,223],"over":[11],"controls":[12],"in":[13,60,212,216,228],"metastatic":[14,229],"renal":[15,230],"cell":[16],"carcinoma,":[17],"and":[18,98,127,174,189,202,235],"none":[19],"has":[20],"been":[21],"performed":[22,151],"using":[23],"interleukin-2.":[24],"The":[25],"Programme":[26],"Etude":[27],"Rein":[28],"Cytokines":[29],"(PERCY)":[30],"Quattro":[31],"trial":[32],"was":[33,93,116,132,150],"designed":[34],"to":[35,43,65,142,160],"evaluate":[36],"both":[37,89],"cytokines":[38],"for":[39,53,107,250],"their":[40],"intermediate":[44,233],"prognosis":[45],"patients,":[46],"who":[47],"represent":[48],"majority":[50],"candidates":[52],"these":[54,251],"treatments.":[55],"METHODS:":[56],"Patients":[57],"were":[58,121,147,164,208],"a":[61,77,86,108,153,238],"2-by-2":[62],"factorial":[63],"design":[64],"medroxyprogesterone":[66],"acetate":[67],"200":[68],"mg":[69],"daily,":[70,84],"9":[72,81],"million":[73,82],"IU":[74,83],"3":[75,111],"times":[76],"week,":[78],"subcutaneous":[79],"interleukin-2":[80,188,221],"or":[85,184],"combination":[87],"cytokines.":[90],"Tumor":[91],"response":[92,124],"evaluated":[94],"at":[95],"Week":[96],"12":[97],"Month":[99],"6;":[100],"progression-free":[101],"patients":[102,146,173,177,192,214],"received":[103],"further":[104],"identical":[105],"treatment":[106],"maximum":[109],"additional":[112],"months.":[113],"Primary":[114],"endpoint":[115],"overall":[117],"survival;":[118],"secondary":[119],"endpoints":[120],"disease-free":[122],"survival,":[123],"rate,":[125],"toxicity,":[126],"quality":[128],"life.":[130],"Survival":[131],"analyzed":[133],"on":[134],"an":[135],"intent-to-treat":[136],"basis.":[137],"RESULTS:":[138],"From":[139],"January":[140],"2000":[141],"July":[143],"2004,":[144],"492":[145],"enrolled.":[148],"Analysis":[149],"after":[152],"29.2-month":[154],"median":[155],"follow-up":[156],"(range,":[157],"0":[158],"months":[159],"54.6":[161],"months).":[162],"There":[163],"no":[165,225],"significant":[166,239],"differences":[168],"between":[169,185],"244":[171],"interferon-alfa-treated":[172],"248":[175],"noninterferon-alfa":[176],"(hazard":[178,193],"ratio,":[179,194],"1.00;":[180],"95%":[181,196],"CI,":[182,197],"0.81-1.24)":[183],"247":[187],"245":[190],"noninterleukin-2-treated":[191],"1.07;":[195],"0.87-1.33;":[198],"log":[199],"rank,":[200],"0.99":[201],"0.52,":[203],"respectively).":[204],"Grade":[205],"3-4":[206],"toxicities":[207],"significantly":[209],"more":[210],"frequent":[211],"cytokine-treated":[213],"than":[215],"medroxyprogesterone-treated":[217],"patients.":[218,252],"CONCLUSIONS:":[219],"Subcutaneous":[220],"and/or":[222],"provide":[224],"cancers":[231],"prognosis,":[234],"they":[236],"induce":[237],"risk":[240],"toxicity.":[242],"Newly":[243],"available":[244],"angiogenesis":[245],"inhibitors":[246],"should":[247],"be":[248],"preferred":[249]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1978670159","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":12},{"year":2013,"cited_by_count":18},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
